期刊
CANNABIS AND CANNABINOID RESEARCH
卷 8, 期 1, 页码 77-91出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/can.2022.0151
关键词
Alzheimer's disease; Biomarkers; Dementia; Endocannabinoid
Endocannabinoid system biomarkers are associated with the progression and pathological features of Alzheimer's disease. Although not specific enough for diagnosis, they hold promise for prognosis, drug-target engagement, and a better understanding of the disease.
Background: Alterations in the endocannabinoid system (ES) have been described in Alzheimer's disease (AD) pathophysiology. In the past years, multiple ES biomarkers have been developed, promising to advance our understanding of ES changes in AD.Discussion: ES biomarkers, including positron emission tomography with cannabinoid receptors tracers and biofluid-based endocannabinoids, are associated with AD disease progression and pathological features.Conclusion: Although not specific enough for AD diagnosis, ES biomarkers hold promise for prognosis, drug-target engagement, and a better understanding of the disease. Here, we summarize currently available ES biomarker findings and discuss their potential applications in the AD research field.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据